Phase Iib multicenter trial of vorinostat in patients with persistent, progressive, or treatment refractory cutaneous T-cell lymphoma. - Olsen,E.A.; Kim,Y.H.; Kuzel,T.M.; Pacheco,T.R.; Foss,F.M.; Parker,S.; Frankel,S.R.; Chen,C.; Ricker,J.L.; Arduino,J.M.; Duvic,M. (J Clin Oncol, 2007)